NCT06673238View on ClinicalTrials.gov

A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants

PHASE1RecruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

October 29, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Healthy Volunteer
Interventions
DRUG

ABBV-722

Oral Capsule

DRUG

Placebo

Oral Capsule

Trial Locations (1)

60030

RECRUITING

Acpru /Id# 270279, Grayslake

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY

NCT06673238 - A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants | Biotech Hunter | Biotech Hunter